

## Conference Schedule (dates, times, and sessions are subject to change)

### May 11

09:00-09:30     **Welcome Address**  
Room: Congress Hall

**Özlem Türeci**  
Association for Cancer Immunotherapy CIMT, Mainz, Germany

---

09:30-11:00     **Cellular Therapies**  
Room: Congress Hall  
Chair: Johanna Olweus

09:30-10:00  
**Daniel Peeper**  
Netherlands Cancer Institute, the Netherlands  
"Translating the cancer-immune dialogue"

10:00-10:30  
**Michael Lotze**  
University of Pittsburgh Cancer Institute, USA  
"Signal 2 in TIL Therapy for Cancer"

10:30-11:00  
**Edward Green**  
German Cancer Research Institute, Germany  
"Combining machine learning and rapid prototyping to accelerate personalised cell therapies"

---

11:00-12:00     **Meet the Editors**  
Room: Gutenberg Hall A  
Chair: Enes Huduti

11:00-11:20  
**Michael Lotze**  
University of Pittsburgh Cancer Institute, USA  
"TBD"

11:20-11:40  
**Julieta Alfonso**  
Nature Cancer, Germany  
"Science communication from an editorial perspective"

11:40-12:00

**Panagiota BouC**

Cancer Cell, the Netherlands

“Bridging the gap: The future of cancer research and clinical oncology in Cancer Cell”

---

12:00-12:40     **Lunch & Learn Industry Talks**

Room: Congress Hall

Chair: Nadja Salomon

12:00 – 12:20

**Hans Anton Schlößer**

Cologne University Hospital, Germany

“Revisiting shared antigens as therapeutic targets in solid cancers”

*Sponsored by peptides & elephants*

12:20-12:40

**Sara Milosevic**

10x Genomics, Switzerland

“Accelerate translational cancer immunotherapy with 10x genomics high-resolution, single-cell, and spatial analysis”

*Sponsored by 10x Genomics*

---

11:00-13:30     **Lunch**

Room: Rhine Foyer

---

13:30-15:00     **Facilitating Translation**

Room: Congress Hall

Chair: Matthias Gaida

13:30-14:00

**Renata Stripecke**

Cologne University Hospital, Germany

“Humanized mice to facilitate translation of immunotherapies”

14:00-14:30

**Daniela Thommen**

Netherlands Cancer Institute, the Netherlands

“Ex vivo tumor fragments as precision medicine tools to personalize immunotherapy treatment”

14:30-15:00

**Maria Amann**

Roche Glycart, Switzerland

“Targeted Costimulatory Agonists: Learning from Forward and Reverse Translation Approaches”

15:00-15:30 **Flash Talk Session I**

Tumor Biology, Improving Immunity, New Targets & Biomarkers

Room: Gutenberg Hall A

Chair: Enes Huduti

**Giovanna Giacca**

San Raffaele Telethon Institute for Gene and Cell Therapy, Italy

“Hepatocyte-mediated tumor antigen presentation drives systemic CD8<sup>+</sup> T cell dysfunction in gastrointestinal tumors”

**Maud Mayoux**

University of Zurich, Institute of experimental Immunology, Switzerland

“CD4 memory T cells orchestrate therapy-responsive immune niches in colorectal cancer liver metastases”

**Anaïs Eberhardt**

Dermatology Unit, Hospices Civils de Lyon, CH Lyon-Sud, Pierre-Bénite, France

“Autoantibodies neutralizing IFN $\alpha$  improve immune checkpoint blockade in patients with melanoma”

**Tiffany Ho**

Princess Margaret Cancer Centre, University Health Network, Canada

“Porphyrin Nanoparticle-Mediated Photodynamic Immune Stimulation: From Local Therapy to Systemic Anti-Tumor Immunity”

**Kathrin Wellach**

“German Cancer Research Center (DKFZ)”

The HPV16 E6/E7 epitome map: A pan-HLA T cell epitope repertoire as basis for epitope-centric immunotherapies

Room: Gutenberg Hall B

Chair: Janina Freitag

**Mark Sweep**

Radboud University Medical Center

“Tumor-infiltrating lymphocytes from melanoma brain metastases show tumor reactive potential, which is suppressed by dexamethasone”

**Anindhita Meena Muralidharan**

TRON, Germany

“Synergy of adaptive and innate immune response during mRNA-based immunotherapies in the heterogenic and hypermutated KRas/p53 lung NSCLC tumors”

**Anja Ritter**

Uppsala University, Sweden

“Immunostimulatory gene therapy targeting CD40, 4-1BBL and PD-L1 reactivates T cell immunity”

**Heiko Weyd**

German Cancer Research Center (DKFZ), Germany

“Inhibition of the growth factor NIM15 modulates stromal cells and breaks tumor immune resistance”

---

15:00-17:00 **Coffee Break**

Room: Rhine Foyer

15:00-17:30     **Poster Session I**  
Room: North, East and West Foyers

Tumor Biology, Improving Immunity, Novel Targets and Biomarkers

---

17:30-18:30     **Keynote Lecture**  
Room: Congress Hall  
Chair: Cornelis Melief

**Ira Mellman**

Parker Institute for Cancer Immunotherapy and Medici Therapeutics, USA  
“The coming renaissance of cancer immunotherapy”

*Sponsored by BioNTech*

---

18:30-19:30     **Ice Breaker Event**

*Sponsored by biomindz*

## May 12

08:30-10:00 **Improving Immunity**

Room: Congress Hall

Chair: Vincenzo Bronte

08:30-09:00

**Ignacio Melero**

Clínica Universidad de Navarra, Spain

“GDF-15 neutralization and CD137 agonists in the immunotherapy clinical arena”

09:00-09:30

**Anne Rios**

Prinses Máxima Centrum, the Netherlands

“Visualize cancer immunotherapy innovation”

09:30-10:00

**Myriam Chalabi**

Netherlands Cancer Institute, the Netherlands

“Breaking barriers with neoadjuvant immunotherapy”

---

10:00-10:30 **Coffee Break**

Room: Rhine Foyer

---

10:30-12:00 **Short Talk Session I**

Cellular Therapies

Room: Gutenberg Hall A

Chair: Isabel Poschke

**Fritiof Åkerström**

Asgard Therapeutics, Sweden

“Preclinical efficacy and biomarker characterization of a first-in-class in situ tumor-to-dendritic cell reprogramming agent”

**Bianca Broske**

University Hospital Bonn, Germany

“Determinants of Efficient Trafficking of De Novo Designed Minibinders in CAR-T Cells”

**Andreas Dobbstein**

German Cancer Research Center (DKFZ), Germany

“RNA vaccination drives expansion and brain-licensing of T cell receptor T cells in experimental glioblastoma”

**Adil Doganay Duru**

Glycostem Therapeutics B.V.

“Umbilical Cord Blood CD34<sup>+</sup> Hematopoietic Stem Cell-Derived NK Cells in MRD-Positive AML: Clinical Outcomes and a Path Toward Potency-Optimized, Scalable NK Cell Therapies”

**Korbinian N Kropp**

Memorial Sloan Kettering Cancer Center, USA

“Determinants of response and resistance to cancer cell killing by human CD4<sup>+</sup> T cells”

## Jairo Lommen

UMC Utrecht, the Netherlands

“Engineered  $\gamma\delta 2$  T-Cell Receptors Enhance Targeting of Phosphoantigen-Driven Butyrophilin Complexes Across Cancer Therapeutic Formats”

Room: Gutenberg Hall B

Chair: Kilian Wistuba-Hamprecht

## Silvia Menegatti

Institut Curie, France

“SUV39H1 disruption in 1XX CAR T cells improves persistence and durable antitumor responses in primary central nervous system lymphoma”

## Zibo Meng

German Cancer Research Center (DKFZ)

“Integrative Identification, Functional Validation, and Spatial Localization of Tumor-Specific TCR Clonotypes in Pancreatic Cancer”

## Marit Jolien van Elsas

Peter MacCallum Cancer Centre, Australia

“A CRISPR/Cas9 knockout screen of naïve human T cells identifies a key epigenetic target for improved CAR T cell efficacy in solid cancers”

## Marta Velasco Santiago

National Center of Cancer Immune Therapy (CCIT-DK), Denmark

“In situ tumor-to-cDC1 reprogramming improves expansion and anti-tumor activity of TILs for adoptive cell therapy”

## Ralf-Holger Voss

University Medical Center (UMC) Mainz, Germany

“TCAR of a Claudin 6 reactivity benefits from CRISPR/Cas9-guided deletion of endogenous TCRs and proved to be equally functional when redesigned to a safeguarded universal TCAR.”

## Fang Zhao

Universitätsklinikum Essen, Germany

“TIGIT marks circulating tumor-reactive CD8<sup>+</sup> T cells enabling blood-based discovery of therapeutic TCRs in melanoma patients”

---

12:00-14:00    **Lunch**

Room: Rhine Foyer

---

12:30-13:30    **CIMT Members Meeting**

Room: Zagreb (lower Rhine Foyer)

---

12:30-13:30    **Lunch & Learn Industry Talks**

Room: Congress Hall

Chair: Gesa Poetzsch

12:30–12:50

**Przemek Fleszar**

Leica Microsystems, Poland

“Single-cell identity and heterogeneity in its environment: Where innovations push the understanding of Spatial Biology.”

*Supported by Leica Microsystems*

12:50–13:10

**Gianluca Rotta**

BD Biosciences, Italy

“Relationship between CAR spatial organization and CAR-T cell function revealed by imaging flow cytometry and transcriptomic profiling”

*Supported by Becton Dickinson*

---

14:00-15:30     **Clinical Translation**

Room: Congress Hall

Chair: Viktor Umansky

14:00-14:30

**Lennard Lee**

University of Oxford, UK

“The inflection point for AI and cancer vaccine- the UK Cancer Vaccine AI Scientist & Supercomputing project”

14:30-15:00

**Cornelis Melief**

ISAbella Pharma / Leiden University Medical Center, the Netherlands

“Benefit from therapeutic HPV vaccine plus PD-1 blocker depends on pre-treatment PD-L1 cancer tissue expression”

15:00-15:30

**Juliane Walz**

University of Tübingen, Germany

““Peptide-based Immunotherapy – Bench to Bedside Developments””

---

15:30-16:00     **Flash Talk Session II**

Cellular Therapies, Novel Tools & Technologies

Room: Gutenberg Hall A

Chair: Enes Huduti

**Sara Breggion**

San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute, Italy

“In vivo macrophage engineering to deliver new immune-activating molecules to liver metastases”

**Hannah Gelhaus**

German Cancer Research Center (DKFZ), Germany

“Single-cell profiling reveals diverse  $\gamma\delta$  T cell subsets and tumor-reactive  $\gamma\delta$  TCR candidates in isocitrate dehydrogenase mutant glioma”

## Anna Berthel

Helmholtz Institute for Translational Oncology (HI-TRON) and German Cancer Research Center (DKFZ), Germany

“Cellular therapy exploration and optimization with a fully human explant model system”

## Sumit Pawar

Myllia Biotechnology, Austria

“Pooled CRISPR Screening for Drug Target Discovery in Primary Human Macrophages”

Room: Gutenberg Hall B

Chair: Janina Freitag

## Daniel Markus Gievers

German Cancer Research Center (DKFZ), Germany

“Investigations on Tonic Signaling Motifs in a Living CAR-T Library”

## María Alejandra Parigiani

University of Freiburg, Germany

“BRAF Inhibition Enhances Vγ9Vδ2 T Cell Cytotoxicity and Modulates the Tumor Microenvironment in mCRC”

## Christina Maria Scheffler

Peter MacCallum Cancer Centre, Australia

“Triciribine phosphate enhances CAR T cell memory and modulates host immunity for improved efficacy in solid cancers”

## Stanley Odidika

University Hospital Cologne, Germany

“Co-stimulatory architecture in trispecific antibodies programs durable human T-cell immunity against DLBCL”

## Joanna Turley

Imuno Therapeutics, the Netherlands

“Engineering highly specific peptide: HLA targeting antibodies through epitope guided design”

16:00-18:00 **Coffee Break**

Room: Rhine Foyer

---

16:00-18:00 **Poster Session II**

Room: North, East and West Foyers

Cellular Therapies, Novel Tools & Technologies

---

18:00-18:30 **EU Cancer Mission**

Chair: Carl Figdor

## Jan-Willem van de Loo

European Commission, Belgium

“The EU Cancer Mission 5 years on – what we have achieved and outline until 2030”

18:30-19:30     **Breakthrough Lecture**

Room: Congress Hall

Chair: Carl Figdor

**Tyler Jacks**

Massachusetts Institute of Technology, USA

“Probing Tumor-Immune interactions using genetically engineered mouse models”

## May 13

08:30-10:00 **Tumor Microenvironment**

Room: Congress Hall

Chair: Sjoerd van der Burg

08:30-09:00

**Anna Obenauf**

Research Institute of Molecular Pathology/IMP, Austria

“Unlocking immunity: Decoding and reprogramming the immune-evasive tumor microenvironment”

09:00-09:30

**Zlatko Trajanoski**

Medical University of Innsbruck, Austria

“Neutrophils: targets for cancer immunotherapy?”

09:30-10:00

**Marij Welters**

Leiden University Medical Center, the Netherlands

“Immune landscape of oropharyngeal squamous cell carcinoma using spatial single cell transcriptomics”

---

10:00-10:30

**Coffee Break**

---

10:30-12:00

**Short Talk Session II**

Improving Immunity, New Targets & Biomarkers

Room: Gutenberg Hall A

Chair: Angelika Riemer

**Joke M. M. den Haan**

Amsterdam UMC, the Netherlands

“CD169/Siglec-1-guided VHH antigen-delivery platform for cancer immunotherapy”

**Chiara Maria Cattaneo**

Humanitas Research Hospital, Italy

“Mismatch Repair-Proficient Colorectal Cancer can evade Immune Surveillance Through an Intrinsic Suppressive Program”

**Leyuan Ma**

University of Pennsylvania and Children's Hospital of Philadelphia, USA

“Vaccine stimulation of bystander t cells in the lymph node unexpectedly promotes tumor-specific host immunity to regress solid tumors”

**Lena Wiedmann**

BioNTech SE, Germany

“Combining the bispecific antibodies pumitamid (BNT327, PD-L1×VEGF-A) and BNT314 (EpCAM×4-1BB) enhances T-cell mediated cytotoxicity and antitumor activity in preclinical studies”

## Syrine Abdeljaoued

EFS BFC, France

“Circulating T cells poised for tissue-resident memory differentiation define response to immune Checkpoint inhibitors: A pan cancer study”

## Michail Angelos Pavlidis

Evaxion A/S, Denmark

“Immune signatures associated with clinical response to the personalized neoantigen vaccine EVX-01 and pembrolizumab in advanced melanoma”

---

### 10:30-12:00 Short Talk Session III

Improving Immunity, New Targets & Biomarkers

Room: Gutenberg Hall B

Chair: Renata Stripecke

## Simon Krost

Hopp-Kindertumorzentrum Heidelberg – KITZ, Germany

“Reprogramming the Tumor Microenvironment Enables T Cell-Mediated Immunotherapies in (Pediatric) Solid Cancers”

## Christoph Heuser-Loy

University Hospital Bonn, Germany

“Resetting microbial alterations in metastatic lungs potentiates anti-PD-1-driven T memory stem cell-associated tumor control”

## Luc Magré

Erasmus MC, the Netherlands

“A novel PD-1 targeted IL-12 mutein construct to specifically activate intratumoral T cells”

## Yenkel Grinberg-Bleyer

Cancer Research Center of Lyon, France

“Regulation of T-cell responses to cancer by the NF-kappaB family of transcription factors”

## Benjamin Ruf

University Hospital Tübingen, Germany

“Activating Mucosal-Associated Invariant T (MAIT) cells for next generation immunotherapy of liver cancer”

## Sonja Schembecker

Hertie Institut Tübingen, Germany

“Characterizing CSF B cell derived antibody targets TMOD4, SPDL1, AKR1A1 and LGALS1 in cancer patients with leptomeningeal tumor manifestation”

---

### 12:00-13:00 Short Talk Session IV

Tumor Biology, Novel Tools & Technologies

Room: Gutenberg Hall A

Chair: Marij Welt

## Toszka Bohn

University Medical Center (UMC) Mainz, Germany

“Proton-sensing receptor GPR65 promotes the development of an immunosuppressive tumor microenvironment in solid tumors”

## Sophie Harrison

Monash University, Australia

“FOXO1-overexpressing CAR T cell combination therapy induces tumour regression in a treatment resistant prostate cancer model”

## Markus Elsner

Helmholtz Munich, Germany

“MouseMapper: Whole-body imaging, AI quantification, and spatial omics reveal systemic disease landscapes”

## Xu Holtkotte

Helmholtz Institute for Translational Oncology (HI-TRON), Germany

“Assessing TCR T cell therapies for solid tumors using 3D bioprints”

---

### 12:00-13:00 Short Talk Session V

Tumor Biology, Novel Tools & Technologies

Room: Gutenberg Hall B

Chair: Jan Beck

## Beatrice Pinci

CIMA, Spain

“Dynamic visualization of liver immunosurveillance: resident macrophages and conventional type-1 dendritic cells orchestrate local T cell priming and anti-metastatic immunity”

## Enola Roussel

Peter MacCallum Cancer Centre, Australia

“Enhancing chimeric antigen receptor (CAR) T cell therapy for paediatric sarcoma through CAR T engineering and tumour microenvironment rewiring”

## Celina Honhoff

Prinses Máxima Center for pediatric oncology, the Netherlands

“De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell function”

## Daniel Postrach

German Cancer Research Center (DKFZ)

“Polytope epitope barcoding reveals spatial clonal histories in situ.”

---

### 13:00-13:15 Career Talk

Rhine Foyer, upper level

## Gesa Poetzsch

TRON

---

### 13:00-14:00 Lunch

Room: Rhine Foyer

---

### 14:00-15:30 Novel Targets & Emerging Tools

Room: Congress Hall

Chair: TBD

14:00-14:30

**Christoph Bock**

CeMM, Austria

“Programmed Cells? Epigenetics, AI, and Cell Engineering for Cancer and Immunity”

14:30-15:00

**Diether Lambrechts**

KU Leuven, Belgium

“EXPANDING Immune Cells and their Tumor Antigens during Checkpoint Immunotherapy”

15:00-15:30 – Virtual presentation

**Adam Grippin**

University of Texas MD Anderson Cancer Center, USA

“Systemic cytokine production drives antitumor responses to RNA therapeutics.”

---

15:30-16:00 **Poster Awards & Closing Remarks**

Room: Congress Hall

*Sponsored by Immatix*